# Cambridge Enterprise Ventures

> Cambridge Enterprise Ventures is a VC fund backing Biotechnology. See 24 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United Kingdom
- Total investments: 24
- Last investment: Jun 2026
- Lead investor: 21%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/showcase/cambridge-enterprise-ventures/about/
- Website: https://www.enterprise.cam.ac.uk/venture-building-investment/cambridge-enterprise-ventures/

Cambridge Enterprise Ventures is a VC fund in Cambridge focused on Biotechnology and Health Care. Cambridge Enterprise Ventures invest University of Cambridge capital into high impact, high growth Cambridge spin-outs and start-ups.

## Contacts

5 contacts available for Cambridge Enterprise Ventures. Shizune tracks 1 team members at Cambridge Enterprise Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/cambridge-enterprise-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 29% |
| Health Care | 4 | 17% |
| Medical | 3 | 13% |
| Therapeutics | 3 | 13% |
| Manufacturing | 3 | 13% |

25 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 8 | 33% |
| Series A | 4 | 17% |
| Pre-Seed | 3 | 13% |
| Funding Round | 3 | 13% |
| Grant | 2 | 8% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 17 | 71% |
| United States | 3 | 13% |
| Germany | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Christine Martin | Head of Ventures | 1 | https://shizune.co/investors/profile/dr-christine-martin |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TRIMTECH Therapeutics | TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $14M | Seed | Jun 23, 2026 |  |
| Gigaton | Gigaton is a climate technology company developing artificial intelligence to decarbonize energy-intensive industries. It intends to use AI technology to reduce carbon emissions by gigatonnes per year. Its emphasis is on energy-intensive industries like cement, steel, and glass, which account for more than 20% of global emissions. Deep learning isused by Carbon Re's Delta Zero platform for industrial decarbonization to enable rapid development and deployment of new low-carbon industrial processes, designs, and materials. | $26M | Series A | Jun 02, 2026 |  |
| Hacktron AI | Hacktron AI offers autonomous tools that search for vulnerabilities in code. The service provides AI agents that test, find, and prove security issues. Users can connect Hacktron to their code through GitHub for automated security checks. The platform supplies proof of vulnerabilities and patch suggestions. Security researchers also contributetools to assist teams in detecting risks. | $2.9M | Seed | May 13, 2026 |  |
| Barocal | Barocal is a Zero-carbon refrigeration pioneer. | $10M | Seed | May 04, 2026 |  |
| auryx | Turning audible sound into health insights using AI | $2M | Pre-Seed | Apr 30, 2026 |  |
| Semarion | Semarion is a spin-out company from the Cavendish Laboratory at the University of Cambridge, operating at the edge of the physical and life sciences. Semarion combines microchip industry materials and techniques engineering and cell biology to tackle unmet drug screening needs. | $3.8M | Venture - Series Unknown | Mar 31, 2026 |  |
| Immutrin | Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively andspecifically remove established amyloid fibrils. | $87.1M | Series A | Mar 24, 2026 |  |
| Seprify | Impossible Materials envisions future customers consuming more sustainable products produced in a circular economy. They contribute to this future by selling cellulose-based products to businesses. Plant-based cellulose white pigment and opacifier solutions have been developed for a variety of industries. | $15.6M | Series A | Mar 10, 2026 |  |
| xWatts | xwatts is an intelligent energy management system that helps commercial buildings reduce costs and emissions. | $2.2M | Seed | Feb 10, 2026 |  |
| Sparxell | Sparxell creates the next generation of colors and effects. | $5M | Seed | Feb 03, 2026 |  |

10 of 24 investments shown.

## Co-investors
- [Parkwalk Advisors](https://shizune.co/investors/profile/parkwalk-advisors) — VC Fund, 6 deals together
- [Cambridge Innovation Capital](https://shizune.co/investors/profile/cambridge-innovation-capital) — VC Fund, 5 deals together
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund, 3 deals together
- [Cambridge Angels group](https://shizune.co/investors/profile/cambridge-angels-group) — VC Fund, 2 deals together
- [Cancer Research Horizons](https://shizune.co/investors/profile/cancer-research-technology) — VC Fund, 2 deals together
- [Dementia Discovery Fund](https://shizune.co/investors/profile/dementia-discovery) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Cambridge Enterprise Ventures invest in?

Cambridge Enterprise Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 24 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Cambridge Enterprise Ventures?

Public channels for Cambridge Enterprise Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Cambridge Enterprise Ventures?

The team at Cambridge Enterprise Ventures includes Christine Martin (Head of Ventures). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co